Cover Image
市場調查報告書

Intarcia Therapeutics, Inc. - 產品平台檢討

Intarcia Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 200968
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Intarcia Therapeutics, Inc. - 產品平台檢討 Intarcia Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年07月08日 內容資訊: 英文 24 Pages
簡介

Intarcia Therapeutics, Inc. 是開發、銷售需要長期治療的疾病治療藥的生物製藥企業。譬如該公司產品便被用於第二型糖尿病和肥胖的治療上。其特徵為讓治療性蛋白質,及胜肽,讓抗體斷片,以及獨家的皮下藥物輸送系統穩定下來的研究開發力。

本報告提供Intarcia Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Intarcia Therapeutics, Inc.的基本資料

Intarcia Therapeutics, Inc. 概要

  • 主要資訊
  • 企業資料

Intarcia Therapeutics, Inc. :研究開發概要

  • 主要的治療範圍

Intarcia Therapeutics, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Intarcia Therapeutics, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式

Intarcia Therapeutics, Inc.:藥物簡介

  • exenatide
  • ITCA-880
  • ITCA-884

Intarcia Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Intarcia Therapeutics, Inc.:最近的開發平台趨勢

Intarcia Therapeutics, Inc.:暫停中的計劃

Intarcia Therapeutics, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07345CDB

Summary

Global Markets Direct's, 'Intarcia Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Intarcia Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Intarcia Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Intarcia Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Intarcia Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Intarcia Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Intarcia Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Intarcia Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Intarcia Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Intarcia Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Intarcia Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Intarcia Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Intarcia Therapeutics, Inc. Snapshot
    • Intarcia Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Intarcia Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Intarcia Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Intarcia Therapeutics, Inc. - Pipeline Products Glance
    • Intarcia Therapeutics, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Intarcia Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
  • Intarcia Therapeutics, Inc. - Drug Profiles
    • exenatide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ITCA-880
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ITCA-884
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Intarcia Therapeutics, Inc. - Pipeline Analysis
    • Intarcia Therapeutics, Inc. - Pipeline Products by Target
    • Intarcia Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Intarcia Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Intarcia Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Intarcia Therapeutics, Inc. - Recent Pipeline Updates
  • Intarcia Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Intarcia Therapeutics, Inc., Key Information
  • Intarcia Therapeutics, Inc., Key Facts
  • Intarcia Therapeutics, Inc. - Pipeline by Indication, 2015
  • Intarcia Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Intarcia Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Intarcia Therapeutics, Inc. - Phase III, 2015
  • Intarcia Therapeutics, Inc. - Phase I, 2015
  • Intarcia Therapeutics, Inc. - Pipeline by Target, 2015
  • Intarcia Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Intarcia Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Intarcia Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Intarcia Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Intarcia Therapeutics, Inc., Other Locations

List of Figures

  • Intarcia Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Intarcia Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Intarcia Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Intarcia Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Intarcia Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top